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ABSTRACT
SIGNALING CHARACTERIZATION OF UP-REGULATION OF MOUSE AND
HUMAN BILE SALT EXPORT PUMP (BSEP) EXPRESSION BY BERBERINE
Yuan Le

Bile salt export pump (Bsep) is primarily responsible for biliary excretion of bile
salts in the liver. Genetic mutation or drug-induced dysfunction of Bsep often leads to
disruption of enterohepatic circulation of bile acids and consequently cholestatic liver
injury. Berberine (BBR), a traditional herbal medicine, promotes bile flow and has been
suggested to treat liver diseases, including cholestasis. We recently reported that BBR
induces Bsep expression in mouse liver. However, the underlying mechanism by which
BBR induces Bsep expression is unknown. My dissertation project showed that BBR
induced mouse and human Bsep/BSEP mRNA and protein expression. In addition, BBR
increased Bsep/BSEP transport activity, evidenced by increased cellular efflux of
dichlorofluorescin diacetate, a selective Bsep substrate. BBR activated NRF2 signaling in
human hepatoma cells, which contributed to BBR-induced human BSEP expression.
However, activation of Nrf2 signaling was not essential for induction of mouse Bsep by
BBR because BBR continued to increase Bsep expression in Nrf2-null mouse liver and
Nrf2-silenced mouse hepatoma cells. In addition, BBR reversed LPS-decreased mouse
Bsep expression in both mouse liver and cultured mouse hepatoma cells. Mechanistically,
BBR attenuated LPS-activated TLR4-NF-кB signaling, which may contribute to BBRinduced mouse Bsep expression. In conclusion, BBR induced human BSEP expression

through NRF2 activation; whereas BBR induced mouse Bsep expression most likely
through TLR4 inhibition.
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CHAPTER 1 INTRODUCTION
1. Overview
Cholestasis is liver disease with impaired bile flow, primarily caused by impaired
hepatic secretion or biliary obstruction (Reichen et al., 1994). Occurrence of cholestasis
is increasing in prevalence worldwide (Beste et al., 2015; Asrani, et al., 2013, 2019).
Current research on cholestasis primarily focuses on the characterization of mechanisms
by which cholestasis is produced, and the investigation of effective therapies to attenuate
the progression of cholestasis. We have previously reported that berberine (BBR), a
traditional herbal medicine historically used to treat bacterial infections, promote bile
flow and increase expression and transport function of Na+-taurocholate cotransporting
polypeptide (Ntcp), the major liver bile acid uptake transporter , by inhibiting Jak2-Stat5
signaling (Bu et al., 2017). During this study, we also found that BBR induces mRNA
expression of bile salt export pump (Bsep), the major liver bile acid efflux transporter, in
mouse liver. The results of my dissertation project further demonstrated that BBR
induces expression of mouse and human Bsep/BSEP transporter gene through different
mechanisms.
In Chapter 1, the current understanding and ongoing research of traditional herbal
medicine BBR, including its pharmaceutical applications, pharmacokinetics, and
toxicological profiles are reviewed. In addition, the function and regulation of Bsep
transporter is briefly discussed. In Chapter 2, methodology and experimental design is
discussed. The results for the impact of Nrf2 activation on BBR-induced mouse and
human Bsep/BSEP and the impact of TLR4 inhibition on mouse Bsep are determined in
Chapter 3 and discussed in Chapter 4. In Chapter 5, the significance and overview of my
1

dissertation are summarized. In addition, the potential future directions of my dissertation
are identified and discussed.
2.

Traditional Herbal Medicines
Traditional herbal medicines are widely used in approximately 80 percent of

developing countries because of their relatively less toxicity and cheap price (Chung et
al., 2012; Quartey et al., 2012; Tillhon et al., 2012).
Traditional herbal medicine generally consists of multiple active components, which
work together to generate their therapeutic-effectiveness (Zhu and Woerdenbag, 1995).
Recently, herbal medicine attracts more attention, especially its characteristic active
components. For instance, berberine (BBR), a very old herbal medicine extracted from
goldenseal and Hunaglian, has been extensively investigated because of its promising
therapeutic potentials, including its anti-oxidative, anti-inflammatory, and anti-diabetic
effects (Vickers et al., 2001; Tillhon et al., 2012). In addition, herbal medicine is very
popular in the U.S. market, where several billions were spent on related products
annually (Vickers et al., 2001).
However, some drawbacks restrict the therapeutic applications of herbal medicine.
For instance, herbal medicine normally contains a mixture of different substances. Thus,
it is difficult to identify and purify the exact active component (Bandaranayake, 2006). In
addition, exploring the mechanism of action of herbal medicines is also challenging
because the synergistic or antagonistic interaction among different components
(Bandaranayake, 2006). Moreover, herbal medicine generally contains extremely low
concentrations of active components, leading to low clinical efficiency (Firenzuoli and
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Gori, 2007). Furthermore, few data are available for toxicological profiles of herbal
medicine (Bandaranayake, 2006).
With the rapid development and emergency of advanced separation methodology,
especially HPLC-MS/MS, increased number of active components of herbal medicine
have been separated and identified (Yang et al., 2009). In addition, more elaborated
animal studies have been conducted to investigate the mechanisms of action and the
recommended dose of herbal medicine (Firenzuoli and Gori, 2007; Yi et al., 2013). All of
above advancements promote the applications of traditional herbal medicine in disease
diagnosis, prevention and therapy.
In my dissertation, I report that BBR, a major active component in several herbal
medicines, such as goldenseal, Oregon grape and barberry, can induce expression and
transport function of Bsep, and thus can promote bile flow and relive endotoxemiainduced cholestasis.
3. Berberine (BBR)
Berberine (BBR), a cationic plant alkaloid, was originally isolated from Xanthoxylon
cava by Cheballier and Pelletan in 1826 (Hahn and Ciak,1975). BBR can also be
extracted from root, stem, bark, fruit and rhizome of other herbal medicine, such as
Hydrastic canadenis (goldenseal) and Berberis vulgaris (barberry). In general, BBR is
the major active component of above mentioned herbal medicine (Hahn and Ciak,1975;
Harmon, 1990; Ivanovska and Philipov, 1996).
BBR has yellow fluorescence color and has been applied as a common fiber reactive
dye in the textile industry and a special cell staining dye in the laboratory (Saxena and
Raja, 2014; Weiß and Brandl, 2013). Herbal medicine containing BBR is extensively
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used in India (Berberis aristata Linn), China (Huang Lian or Copis chinesis) and North
America (Hydrastis canadensis) as the dietary supplement and folk remedies (Hahn and
Ciak,1975; “Huang Lian”, 1986; McKenna and Plotnikoff 2005; Komal et al., 2011;
Upton, 2011).
BBR shows broad pharmaceutical applications. Traditionally, BBR is used as an
antibiotic (Hahn and Ciak,1975; Tillhon et al., 2012). It has been thought that its
isoquinoline nucleus with quaternary nitrogen and methylenedioxy structure on C-2 and
C-3 is essential for its anti-microbial property (Fig. 1.3) (Qing et al., 2017). In addition,
positive charge of BBR can facilitate the interaction to negatively charged biological
molecules, including bacteria DNA and RNA, and thus can inhibit bacteria growth
(Davidson et al., 1977; Creasey, 1979; Bhadra et al., 2010). Furthermore, BBR has also
been used to treat infections caused by fungi and protozoan (Amin et al., 1969; Basha et
al., 2002).

Methylenedioxy

Isoquinoline nucleus

Figure 1.3 Chemical structure of berberine (BBR)
Isoquinoline nucleus and methylenedioxy structure of BBR as highlighted by red and
blue circles, respectively.
4

Recently, BBR also shows potential to treat inflammatory diseases, type II diabetes
and cancers. BBR suppresses inflammation most likely through blocking Toll-like
receptor (TLR) 4-NF-кB inflammatory pathway, as well as inhibiting the synthesis of
pro-inflammatory cytokines (Remppis, et al., 2010; Lou et al., 2011). BBR also
suppresses the binding efficiency of lipopolysaccharides (LPS) to TLR4 (Kim et al,
2004; Chu et al., 2014). In addition, BBR scavenges oxidative stress and modulates
inflammation via activation of Nrf2 signaling, which play important anti-oxidative and
anti-inflammatory roles (Mo et al., 2014). The mechanisms by which BBR activates Nrf2
include the activation of PI3K/Akt-Nrf2 signaling and/or by following up-regulation of
the expression of one LncRNA, MARK052686 (Hsu et al., 2012; Chen et al., 2012; Chen
et al., 2014; Yuan et al., 2015). Next, BBR has been applied to treat type II diabetes
because it increases glucose metabolism and insulin sensitivity via AMPK activation
(Creasey, 1979; Yin et al., 2008; Brusq et al., 2006; Lee et al., 2006). BBR can also
relieve diabetes-related complications, such as diabetic cardiovascular complications
through preventing oxidative stress and reducing nitric oxide or cholesterol synthesis
(Yin et al., 2012). Moreover, BBR is a putative chemotherapeutic agent by inhibiting
DNA topoisomerases, p53-depedent cell growth, Akt signaling and cell division
progression (Kobayashi et al., 1995; Serafim et al., 2008; Choi et al., 2009; Liu et al.,
2011; James et al, 2011; Kuo et al., 2012).
More and more evidence indicates that BBR has hepatoprotective effects by
preventing the progression of hepatocellular carcinomas, non-alcoholic fatty liver
(NAFLD), cholestasis, liver fibrosis, and drug-induced liver injury (DILI) (Wei and
Gilani, 2000; Zhang et al., 2008; Sun et al., 2009, 2017; Liu et al., 2013). BBR promotes
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autophagic cell death and mitochondrial apoptosis in hepatocellular carcinoma cells
(Wang et al., 2010). The mechanisms by which BBR ameliorates liver diseases involve
anti-oxidative and anti-inflammatory effects, as well as improving lipid profile (Mo et al.,
2014; Fan et al., 2015; Wei, et al., 2016). For instance, BBR prevents chemical-induced
hepatotoxicity and attenuates the progression of NAFLD in rats through Nrf2 activation
(Deng et al., 2019). Similar to animal study, BBR attenuates the progression of NAFLD
in patients, indicated by down-regulation of serum triglycerides, low-density lipoprotein
(LDL), alanine aminotransferase (ALT) and HemoglobinA1C (HbA1C) (Yan et al.,
2015). In addition, goldenseal, in which BBR is the major active component, promotes
bile flow (Newall, et al., 1996; Liu et al., 2013; Guo et al., 2016). We and others already
reported that BBR induces the expression of Ntcp and Bsep, two bile acid transporters in
mouse livers (Guo et al., 2016; Bu et al., 2017).
In addition to pharmaceutical effectiveness and safety, the pharmacokinetics of BBR
has been well-documented. For example, oral administration of BBR shows extremely
low bioavailability, which is less than 1% and 5% in human and rat, respectively (Chen et
al., 2011; Liu et al., 2010; Liu et al., 2016). The low bioavailability of BBR is due to
poor absorption, intestinal first-pass elimination and/or transporter-mediated efflux (Chen
et al., 2011; Liu et al., 2010; Liu et al., 2016). After absorption, BBR primarily
distributes to liver and can also be detected in kidney, muscle, lung, brain and heart in
small amounts (Tan et al., 2013). In the liver, BBR is uptaken and effluxed by organic
cation transporter (Oct)-1 and multidrug-resistance protein (MDR)1, respectively (Nies et
al, 2008). BBR can be metabolized into four metabolites, including berberrubine (M1),
thalifendine (M2), demethyleneberberine (M3) and jatrorrhizine (M4) by cytochrome

6

p450 (CYP) enzymes, including CYP1A2, CYP2D6 and CYP3A4 (Tsai and Tsai, et al.,
2002; Nies et al., 2008; Li et al., 2011; Tan et al., 2013). Finally, BBR is primarily
eliminated through the urinary system (Chen and Chang, 1995; Tsai and Tsai, 2004). The
half-life of BBR in rat serum and liver is 12.5±1.6 and 29.4±5.7 minutes, respectively
(Tsai and Tsai, 2002). As a result, the effective doses of BBR in rodents are relatively
higher because of poor absorption and short half-life.
Toxicological profile of BBR has also been reported. Oral LD50 of BBR is 1,000
mg/kg in rats and 329 mg/kg in mice (Haginiwa et al.,1962; Kheir et al., 2010; Yi, et al.,
2013). To estimate the safe dose, mice were orally administrated with high doses of BBR
for 6 hours. The limit of safety dose of BBR is 20.8 g/kg, which did not produce apparent
mouse mortality (Kheir et al., 2010). There is no clear LD50 value or dose-response
relationship of BBR toxicity in humans (Mills et al., 2004; Kheir et al., 2010). According
to the safety dose in mice, the predicted safety dose of BBR in patients is about 2.97 g/kg,
approximate 1 x 10 3 times higher than the clinical dose (Kheir et al., 2010). In general,
BBR has been clinically used from 100 to 1,000 mg/kg/day without producing apparent
toxicities (Vuddanda et al., 2010; Yin et al., 2008).
However, it has been reported that extremely high doses or chronic treatment of
BBR could induce side effects and toxicities. For example, BBR can induce
cardiotoxicity in dogs and immune toxicity in mice (Affuso et al., 2010; Mahmoudi et al.,
2016). In addition, BBR may induce jaundice in pregnant women and kernicterus in the
neonates by replacing bilirubin from its binding protein in rat serum and thus, resulting in
an increase of serum level of bilirubin (Chan, 1993). Moreover, chronic treatment of
BBR can induce gastrointestinal side effects, such as diarrhea and constipation in patients
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(Kowalewski et al., 1975; Bateman et al., 1998; Imanshahidi and Hosseinzadeh, 2008;
Affuso et al., 2010)
4. The Major Bile Acid Transporters in the Liver
Bile acid transporters are located at both sinusoidal and canalicular membranes of
hepatocytes, which transport either unconjugated or conjugated bile acids, or both
(Roberts et al., 2002; Klaassen and Aleksunes, 2010).
The primary function of liver bile acid transporters is to help to maintain bile acid
homeostasis (Klaassen and Aleksunes, 2010). As shown in Figure 1.4, Na +-taurocholate
cotransporting polypeptide (Ntcp) is the major liver bile acids uptake transporter. Bile
salt export pump (Bsep) is the major liver bile acids efflux transporter (Roberts et al.,
2002). Both Ntcp and Bsep can control bile flow in the liver. In addition, some other
transporters can also contribute to hepatic transport of bile acids. For example, organic
anion transporting polypeptides (Oatps) facilitate bile acids uptake. Multidrug resistanceassociated proteins (Mrps) 2 and 3 are responsible for hepatic efflux of bile acids
(Roberts et al., 2002).
Disruption of bile flow or dysfunction of bile acid transporters often leads to
cholestasis and even liver fibrosis and ultimately cirrhosis (Trauner et al., 1998; Roberts
et al., 2002; Byrne et al., 2002; Klaassen and Aleksunes, 2010;). For example,
suppression or genetic knockout of Ntcp causes extrahepatic cholestasis in rats (Gartung
et al., 1996). Mutations of BSEP gene cause type 2 progressive familial intrahepatic
cholestasis (PFIC2) in patients (Paulusma et al., 1997; Strautnieks et al., 1998; Anwer,
2004). In addition, patients with cholestatic liver injury often show disrupted or reduced
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expression of hepatic bile acid transporters, including NTCP, MRPs and BSEP (Zollner
et al., 2001; Anwer, 2004).

Figure 1.4 Major bile acid transporters in the hepatocyte
Ntcp and Oatp are responsible for hepatic uptake of bile acids whereas Bsep, Mrp2 and
Mrp3 are responsible for cellular efflux of bile acids.
5. Bile Salt Export Pump (Bsep)
Bile salt export pump (Bsep), also named ATP-binding cassette (ABC) transporter
family B member 11 (ABCB11), is predominantly expressed in the canalicular membrane
of hepatocytes (Török et al. 1999; Meier and Stieger, 2002). In addition, Bsep is
minimally detected in other tissues (Török et al. 1999).
Bsep has 12 membrane-spanning helices, which are functionally grouped into two
transmembrane domains (Gerloff et al. 1998). Bsep utilizes the energy from ATP
hydrolysis to facilitate the efflux of its substrates against a concentration gradient (Meier
and Stieger, 2002). Bsep transports primarily monovalent bile acids, including taurine
and glycine conjugated bile acids, and some secondary bile acids, such as deoxycholic
acid, as well as certain drugs, cyclosporine and rifamycin (Byrne et al., 2002; Stieger,
2011).
9

The regulation of Bsep expression has been extensively investigated. It is wellestablished that Bsep can be up-regulated following FXR activation, a master regulator
that can sense the alteration of bile acid homeostasis (Parks et al., 1999;
Ananthanarayanan et al., 2001; Gerloff et al., 2002). FXR signaling can be activated by
bile acids, such as chenodeoxycholic acid (CDCA) (Makishima et al., 1999; Parks et al.,
1999). Activated FXR forms heterodimer with retinoid X receptor (RXR) alpha, and then
binds to Inverted repeat-1 (IR-1) response elements in the promoter of its target genes to
induce or suppress their expression (Makishima et al., 1999; Parks et al., 1999). In
addition, Nrf2 signaling can up-regulate human BSEP expression in cultured human
hepatoma cells (Weerachayaphorn et al., 2009). Nrf2 activation is also essential for Bsep
expression under ischemia condition in rat liver (Kim et al., 2019). However, Nrf2
activation appears not to induce mouse Bsep expression (Klaassen and Reisman, 2010).
Bsep expression can be down-regulated by estrogens (Crocenzi et al., 2003). For
instance, estradiol-17β-D-glucuronide (E217G) inhibits Bsep transport function in rat
liver (Crocenzi et al., 2003). In addition, lipopolysaccharides (LPS), the endotoxins
extracted from outer membrane of Gram-negative bacteria can activate Toll-like receptor
(TLR) 4 and then inhibit Bsep expression through NF-кB, the downstream inflammatory
pathway (Adachi et al., 1998; Jiang et al., 2000; Shimazu et al., 1999; Sherry and
Cerami, 1988; Raetz and Whitfield, 2002; Zollner et al., 2001; Hartmann et al., 2002).
Furthermore, many drugs, like bosentan can inhibit Bsep efflux function in both in vivo
and in vitro studies (Fattinger, et al., 2001).
Genetic mutations or dysfunction of Bsep often lead to bile acid accumulation and
consequently cholestasis in patients (Anwer, 2004). Mechanistically, genetic mutations of
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Bsep often lead to disruption of mRNA expression stability, alterations of BSEP
targeting, and even shorter half-life of Bsep expression and turnover time in the
membrane (Trauner and Boyer, 2003; Kullak-Ublick et al., 2004; Anwer, 2004).
Therefore, mutations of Bsep gene cause defective bile secretion and severe cholestasis in
the children, such as in the patients with progressive familial intrahepatic cholestasis
(PFIC) 2 (Strautnieks, et al., 1998; Jansen et al., 1999). In addition, drug-induced
cholestasis is often accompanied by reduced Bsep expression (Byrne et al., 2002). For
example, cyclosporin and rifampicin, two validated competitive Bsep inhibitors, cause
drug-induced liver injury (DILI) in patients (Byrne et al., 2002). Therefore, reversal of
decreased Bsep expression can help to attenuate the progression of cholestasis.
6. Aims
We propose that the effects of BBR to increase bile flow is partly mediated by upregulation of expression of major hepatic bile acid transporters, including Ntcp and Bsep.
We have previously reported that BBR induced Ntcp expression via inhibition of Jak2Stat5 signaling (Bu, et al., 2017). The study objective of my dissertation focuses on
characterization of regulation of Bsep expression by BBR. Specifically, I determined
whether BBR induces Bsep expression and its transport function. In addition, the roles of
Nrf2 and TLR4 signaling in BBR-induced Bsep/BSEP expression have been investigated.
Specifically, in the first hypothesis, I determined the impact of Nrf2 activation on
Bsep/BSEP induction by BRR. In the second hypothesis, I proposed that BBR induced
mouse Bsep through TLR4 inactivation.
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CHAPTER 2 METHOLOGY
1. Chemicals and Reagents
Berberine chloride was purchased from Alfa Aesar (cat. # AAJ6231106; Tewksbury,
MA). Tak242 was purchased from Millipore (cat. # 50-833-600001; Burlington, MA).
Lipopolysaccharides (LPS) was purchased from InvivoGen (cat. # NC0202558; San
Diego, CA). Analysis kits of serum alanine aminotransferase (ALT) (cat. # A7526 -150)
and aspartate aminotransferase (AST) (cat. # A7561-150) were purchased from Pointe
Scientific, Inc. (Ann Arbor, MI). Analysis kits of glucose (cat. # TR15221), triglycerides
(cat. # TR22421) and cholesterol (cat. # TR13421), mem-PER Plus membrane protein
extraction kit (cat. # 89842), NE-PER Nuclear and cytoplasmic extraction reagent kit
(cat. # 78833), and Lipofectamine 2000 (cat. # 11668027) were purchased from Thermo
Fisher Scientific Inc. (Waltham, MA). Chemiluminescent HRP Substrate (cat. #
WBKLS0100) for Western blotting was purchased from Millipore (Billerica, MA).
Zymoclean Gel DNA Recovery kit (cat. # D4001), Zymo Plasmid Miniprep kit (cat. #
D4036) and DNA Clean & Concentrator kit (cat. # D4013) were purchased from Zymo
Research Corporation (Irvine, CA). All other reagents and chemicals, unless specifically
indicated, were purchased from Thermo Fisher Scientific Inc. (Waltham, Massachusetts).
2. Animal and Treatment
Approximately 8 weeks of age of male C57BL/6 wild-type mice (cat. # 000664),
TLR4-mutated mice, C3H/HeJ (cat. # 00659) and corresponding wild-type mice,
C3H/OuJ (cat. # 00635) were purchased from the Jackson Laboratory (Bar Harbor,
Maine). Nrf2-null mice, originally engineered in the Laboratory of Dr. Jefferson Chan at
the University of California (Irvine, CA), were bred in the animal center at St. John’s
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University. All animals were maintained under a standard 12-hour light: dark cycle with
free access to regular rodent chow and water ad libitum. To mimic the clinical use of
BBR, oral administration is used in animal study. In the studies to test Hypothesis I, both
wild-type and Nrf2-null mice were orally treated with BBR (30 or 100 mg/kg) once daily
for 14 days (n=6/treatment). Control group received saline. In the studies of Hypothesis
II, mice were randomly divided into four groups and treated with 1) BBR (100 mg/kg;
p.o.) once daily for 7 days; 2) LPS (2 mg/kg; i.p.) for 12 hours; 3) BBR (100 mg/kg; p.o.)
for 7 days following LPS (2 mg/kg; i.p.) for 12 hours. Control group received saline (p.o.
or i.p.). According to previous reports, BBR or LPS doses used in this study will alter
Bsep expression and will not produce apparent hepatotoxicity (Bu et al., 2017; Li et al.,
2107).
Mouse condition was monitored daily. Either BBR or LPS treatment did not alter the
body weight and animal behavior. After treatment, mouse livers and serum were
collected and stored at -80°C for future analysis. One portion of freshly collected mouse
liver was processed for histology study.
3. Histopathology
After LPS treatment with or without BBR pre-treatment, mouse livers were fixed in
10% formalin and then processed for Hematoxylin and Eosin (H&E) staining.
4. Serum chemical assay
The serum levels of ALT, glucose, triglycerides and cholesterol in wild-type
C57/BL6 mice and serum levels of ALT and AST in wild-type C3H/OuJ mice were
analyzed using commercially available kits according to their instructions.
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5. Cell Culture
Mouse Hepa1c1c7 hepatoma cells (cat. # CRL-2026; ATCC®; Manassas, VA) were
cultured in Corning® MEM (Minimum Essential Medium) Alpha Medium (cat. #
MT15012CV; Corning, NY). Human SNU449 hepatoma cells (cat. # CRL-2234;
ATCC®; Manassas, VA) were cultured in Gibco™ DMEM High Glucose medium (cat. #
11-995-065; Waltham, MA). The cell culture medium was supplemented with 10% heatinactivated fetal bovine serum (Atlanta Biologicals; Norcross, GA). Cells were cultured
at 37°C with 5% CO2 atmosphere. Both mouse and human hepatoma cells were treated
by BBR as we previously described (Bu et al., 2017). Briefly, mouse Hepa1c1c7 or
human SNU449 hepatoma cells were seeded into 6-well plates (3 x105/well) and treated
with BBR (5, 10 or 30 µM), in triplicate (Zhai et al., 2008; Bu et al., 2017). Mouse
Hepa1c1c7 cells were also treated with LPS (10 ng/mL) in the presence or absence of
BBR (10 µM) or Tak242 (0.3 mM), in triplicate. Control group received fresh medium.
After 24 and 48 hours treatment, cells were collected and processed for mRNA and
protein analysis, respectively.
6. Transfection of siRNA
The small interfering RNAs (siRNA) against mouse (cat. # L-003755-00-0005) or
human Bsep/BSEP (cat. # L-04076655-00-0005), as well as nontargeting negative control
siRNA (cat. #D0018101005) were purchased from Dharmacon TM(Lafayette, CO). Mouse
Hepa1c1c7 and human SNU449 hepatoma cells were transfected to test silence efficiency
using Lipofectamine messengerMAX TM reagent per manufacturer’s instructions (cat. #
LMRNA003; Life Technologies; Carlsbad, CA). The successful gene silence should
knockdown more than 75% of mRNA expression of target gene. After BBR treatment (10

14

µM) for 24 hours, cells were then collected and performed quantitative RT-PCR for
mRNA analysis.
7. Quantitative Real time-PCR (qRT-PCR) assay
Total RNAs from mouse liver and cultured hepatoma cells were extracted using
TRIzol™ RNA extraction reagent (cat. # 15596026; Life Technologies; Carlsbad, CA)
per the manufacturer’s instructions. RNA integrity was assessed by electrophoresis on a
denatured agarose gel containing 3-(N-morpholino) propanesulfonic acid (MOPS) and
formaldehyde. RNA concentrations were spectrophotometrically quantified at 260nm.
Then, total RNAs were reversely transcribed into cDNA using SuperScriptTM II reverse
transcriptase (cat. # 18064014; Life Technologies; Carlsbad, CA). Quantitative RT-PCR
was performed using SYBR™ Select Master Mix (cat. # 4472903; Life Technologies;
Carlsbad, CA) in an AriaMx qRT-PCR system (Agilent Technologies; Santa Clara, CA).
Data was calculated according to the comparative delta-delta CT method. The results
were presented as relative fold of the control. Primers of mouse or human Bsep/BSEP,
Nrf2/NRF2 and its target genes, as well as inflammation genes were listed in Table 2.1.
All quantitative RT-PCR primers were designed using PubMed Primer-BLAST or
Primer3 software (NIH) and synthesized by Integrated DNA Technologies (Coralville,
IA) or Eurofins Genomics (Louisville, KY).
8. Immunocytochemistry (ICC) Staining
Mouse Hepa1c1c7 and human SNU449 hepatoma cells were cultured in chamber
slides (cat. # 12-565-7; Thermo Fisher Scientific Inc.; Waltham, MA) and treated with or
without BBR (5 or 10 μM) for 48 hours. Fixation and blocking were performed as
previously described (Bu et al., 2017). Then, cells were incubated with the antibody
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(1:100) against mouse/human Bsep/BSEP protein (cat. # PAB4697; Abnova; Walnut,
CA) or the antibody (1:100) against mouse/human Nrf2/NRF2 protein (cat. # 12721; Cell
Signaling Technology; Danvers, MA) overnight at 4°C. Next day, chamber slides were
incubated with 1:300 Pierce Goat Anti-Rabbit IgG (H+L) Biotin Conjugated secondary
antibody (cat. # 31820; Thermo Fisher Scientific Inc.; Waltham, MA) for 4 hours at room
temperature. Cells were then washed and incubated with 1:400 Pierce High Sensitivity
Streptavidin-HRP (cat. # 21130; Thermo Fisher Scientific Inc.; Waltham, MA) or
Alkaline phosphatase streptavidin (cat. # SA5100; Vector Laboratories Inc.; Burlingame,
CA) for 1 hour at room temperature. After final wash, color development was achieved
using BCIP/NBT Alkaline phosphatase substrate kit (cat. # SK5400) in Vector
Laboratories Inc. (Burlingame, CA) according to the manufacturer’s instructions.
9. Western Blotting
Membrane and nuclear proteins from mouse liver and hepatoma cells were extracted
using the Mem-PER Plus membrane protein extraction kit and the NE-PER Nuclear and
cytoplasmic extraction reagents kit, respectively. Protein concentrations were quantified
at 280 nm using spectrophotometer. Protein samples (30 ng/lane) were mixed with SDS
loading buffer and heated and separated by 12% or 15% SDS-PAGE gel. After electrotransfer blotting, PVDF membranes were blocked for 2 hours in 1 xTBS supplemented
with 5% non-fat milk or 5% BSA. PVDF membranes were then incubated with the
antibody (1:1,000) against mouse/human Bsep/BSEP protein (cat. # PAB4697; Abnova;
Walnut, CA), the antibody (1:1,000) against mouse/human Nrf2/NRF2 protein (cat. #
12721; Cell Signaling Technology; Danvers, MA) or the antibody (1:1,000) against
mouse and human Bsep/BSEP (cat. # PAB4697; Abnova; Walnut, CA) or antib ody
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(1:1,000) against mouse and human p65-NF-кB (cat. # D14E12; Cell Signaling
Technology; Danvers, MA) in 2.5% BSA at room temperature for 1 hour, followed by
overnight incubation at 4°C. PVDF membranes were then washed and incubated with
Pierce Goat Anti-Rabbit IgG (H+L) Biotin Conjugated secondary antibody (1:5,000;
Thermo Fisher Scientific Inc.; Waltham, MA) in 1XTBS supplemented with 2.5% nonfat milk for 2 hours at room temperature. Last, the membranes were incubated with
Pierce High Sensitivity Streptavidin-HRP (cat. # 21130; 1:5000; Thermo Fisher
Scientific Inc.; Waltham, MA) in 1XTBS supplemented with 0.5% BSA for 30 minutes at
room temperature. Beta-actin (cat. # MA5-15739; 1:2,000; Pierce biotechnology;
Waltham, MA) and Histone-H3 (cat. # 4499; 1:1,000; Cell Signaling Technology;
Danvers, MA) were used as loading controls for membrane and nuclear proteins,
respectively. Immunoreactive protein bands were detected with Immobilon Western
Chemiluminescent HRP Substrate (cat. # WBKL S00 50; EMD Millipore, Billerica,
MA).
10. Analysis of Efflux Transport Function of Bsep/BSEP
The Bsep transport function was analyzed as previously reported (Li et al., 2008).
Specifically, mouse Hepa1c1c7 and human SNU449 hepatoma cells were treated with
BBR (10 µM) and then harvested for 48 hours. Collected cells were washed with cold
1×PBS twice. The cells were aliquoted (1x106 per tube) into a 1.5 mL tube and incubated
with dichlorofluorescin diacetate (cat. # D292648; Sigma-Aldrich; St. Louis, MO), a
selective Bsep substrate for 40 minutes at 4°C. After incubation, cells were washed by
cold 1XPBS twice and re-suspended with 1X PBS and then transferred into a new 1.5 mL
tube. All tubes were incubated with a speed of 300 rpm at 37°C for 1 hour. Then, both
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supernatant and cell pellet following centrifugation were collected. Cells were then
lysated using 10% SDS solution. Dichlorofluorescin diacetate fluorescence was measured
in both supernatant and cell lysate using Tecan Microplate Readers (Männedorf,
Switzerland) at excitation 485 nm and emission 530 nm.
11. Cloning of Bsep/BSEP Gene Promoters of Different Lengths
BAC clones containing mouse Bsep (cat. # RP23-291P1) and human BSEP (cat. #
RP11-527A7) genes were purchased from BACPAC resources (Children's Hospital
Oakland; Oakland, CA). The 2.9-kb of mouse Bsep gene promoter or 3.6-kb of human
BSEP gene promoter was cloned from BAC clones via PCR analysis, and then
engineered into polycloning site of the pGL3-basic vector (cat. # E1751; Promega;
Fitchburg, WI). For truncated promoter constructs, the locations and sequences of the
forward primers, the shared reverse primer were listed in Table 2.2. The sequences of
different lengths of Bsep/BSEP gene promoters that were inserted into pGL3 reporter
construct were validated by DNA sequencing (Eurofins Genomics; Huntsville, AL).
12. Transfection and Dual-Luciferase® Reporter Assay
Recombinant pGL3 reporter constructs were transfected into mouse Hepa1c1c7 or
human SNU449 cells, using Lipofectamine 2000 transfection reagent (cat. # 11668027;
Life Technologies, Inc.; Carlsbad, CA) following the manufacturer's instructions. Briefly,
the cells were seeded onto 96-well tissue culture plates 1 day prior to transfection.
Plasmid DNA (180-200 ng) of the empty pGL3-basic vector (cat. # E1751; Promega,
Fitchburg, WI) or Bsep/BSEP promoter-containing pGL3 reporter constructs, plus 10 ng
of pRL Renilla luciferase reporter vector (cat. # E2261; Promega; Madison, Wisconsin)
was mixed with Lipofectamine 2000 with 1:1 ratio and then dispensed to each well. After
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24 hours of incubation, transfection medium was replaced with fresh med iums with or
without BBR at indicated concentrations. Forty-eight hours later, the cells were lysed and
processed for Dual-Luciferase ® reporter assay per the manufacturer's instructions (cat. #
E1910; Promega; Fitchburg, WI).
13. Statistical Analysis
Data were expressed as mean ± standard error. The data between control and BBRtreated group were analyzed by Student’s t-test. Comparisons between more than two
treatment groups were analyzed by one-way analysis of variance (ANOVA) followed by
Duncan’s post-hoc tests (Sigmaplot; Systat Software, Inc.; San Jose, CA). The statistical
significance was considered when p < 0.05.
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Table 2.1: qPCR primers for analysis of mRNA expression of mouse and human 18s
rDNA, Nrf2, Ho-1, Nqo-1, Bsep and inflammation genes by quantitative RT-PCR
assays

Gene

Accession No.

Forward primer

Reverse primer

18s

NR_003278.3 (m,
h)

GCAATTATTCCCCATG
AACG

GGCCTCACTAAACCA
TCCAA

Nrf2

NM_007824.2 (m) CGAGATATACGCAGG
AGAGGTAAGA

GCTCGACAATGTTCT
CCAGCTT

Ho-1

NM_010012.3 (m) CCTCACTGGCAGGAA
ATCATC

CCTCGTGGAGACGCT
TTACATA

Nqo-1 NM_024264.5 (m) TATCCTTCCGAGTCAT
CTCTAGCA

TCTGCAGCTTCCAGCT
TCTTG

Bsep

NM_031760.1 (m) GGACAATGATGTGCTT CACACAAAGCCCCTA
GTGG
CCAGT

TNFα

NM_001278601.1 GCCTCTTCTCATTCCT
(m)
GCTTG

IL-1β

NM_008361.4 (m) AACCTGCTGGTGTGTG CAGCACGAGGCTTTT
ACGTTC
TTGTTGT

IL-6

NM_001314054.1 ACAACCACGGCCTTCC CACGATTTCCCAGAG
(m)
CTACTT
AACATGTG

NRF2

NM_000780.3 (H) CGGTATGCAACAGGA
CATTG

GTTTGGCTTCTGGACT
TGGA

HO-1

NM_006446.4 (H) GAAAAGCACATCCAG
GCAAT

GCTGCCACATTAGGG
TGTCT

NQO1

NM_019844.3 (H) GTTGCCTGAAAAATG
GGAGA

AAAAACCACCAGTGC
CAGTC

BSEP

NM_003742.4 (H) TGTGGGAAGTTTGTGT
GCAT

ACCCACAACGTGTTC
CATTT
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CTGATGAGAGGGAGG
CCATT

Table 2.2: Sequences of PCR cloning primers of mouse and human Bsep/BSEP
promoter.
Bsep/BSEP promoter

Promoter

Forward primer sequence

region
pGL3-Bsep-2928

-2,843 to +85

P1:
AAGACTGACGCGTGTGAGCTCC
TCT

pGL3-Bsep-2120

-2,035 to +85

P2:
TGGACTTCACGCGTGGGTGAT

Shared reverse primers (m)

AGAGACTCGAGTGTGGAAAGTC
A

pGL3-BSEP-3680

-3,602 to +78

P1: TTCTGCTAGCCTGGGTCTCT

pGL3-BSEP-377

-299 to +78

P2:
GCAACACGCGTTTTCCAAGAG

pGL3-BSEP-178

-100 to +78

P3: TTCCAACGCGTGTTGACAC

Shared reverse primers (H)

CAACCTCGAGTTTCATCATTC
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CHAPTER 3 RESULTS
1. Regulation of Mouse and Human Bsep/BSEP by BBR via Nrf2 Activation
1.1. BBR Decreased Serum Level of Cholesterol in Wild-type Mice
BBR did not increase serum level of ALT, a biomarker of liver injury in wild-type
mice (Fig. 3.1A). BBR at 100 mg/kg tended to decrease serum levels of glucose (Fig.
3.1B) and triglycerides (Fig. 3.1C), and reduced serum levels of cholesterol (Fig. 3.1D).
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Figure 3.1 Effects of BBR on serum chemical levels in wild-type mice.
Wild-type C57BL/6 mouse sera were collected after BBR treatment (0, 30 or 100 mg/kg;
p.o.) once daily for 14 days (n=6/treatment). Mice serum were collected and processed
for serum chemical analysis of ALT (A), glucose (B), triglycerides (C) and cholesterol
(D). Statistical differences (p <0.05) are indicated between BBR and control group (*).
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1.2. BBR Increased Bsep mRNA and Protein Expression in Mouse Liver and
Hepatoma Cells
BBR dose-dependently induced mRNA expression of Bsep in wild-type (Fig. 3.2A)
but not in Nrf2-null mouse livers (Fig. 3.2B). In addition, BBR increased membrane
protein expression of Bsep in both wild-type and Nrf2-null mouse livers (Fig. 3.3A and
B).
BBR induced mRNA expression of Bsep/BSEP in both mouse Hepa1c1c7 (Fig.
3.4A) and human SNU449 (Fig. 3.4B) hepatoma cells. BBR dose-dependently increased
membrane Bsep/BSEP protein expression in both mouse Hepa1c1c7 (Fig. 3.5A) and
human SNU449 (Fig. 3.5B) hepatoma cells. In addition, immunocytochemistry (ICC)
staining showed that BBR increased relative numbers of Bsep/BSEP protein -positive
cells, which further demonstrated that BBR increased mouse and human Bsep/BSEP
protein expression (Fig. 3.6A and B).
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Figure 3.2 Regulation of Bsep mRNA expression by BBR in wild-type and Nrf2-null
mouse livers.
Adult male C57BL/6 wild-type mice and age-matched male Nrf2-null mice were orally
treated with BBR (0, 30 or 100 mg/kg) once daily for 14 days (n=6/treatment). Mouse
livers were harvested 14 days later and processed for quantitative RT-PCR analysis of
Bsep mRNA expression in wild-type (A) and Nrf2-null (B) mouse livers. Statistical
differences (p <0.05) are indicated between BBR and control group (*).
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Figure 3.3 Regulation of Bsep protein expression by BBR in wild-type and Nrf2-null
mouse livers.
Adult male C57BL/6 wild-type and age-matched male Nrf2-null mice were orally treated
with BBR (0, 30 or 100 mg/kg) once daily for 14 days (n=6/treatment). Membrane
proteins, extracted from wild-type (A) and Nrf2-null (B) mouse livers, were processed for
analysis of Bsep protein expression by Western blotting. Statistical differences (p <0.05)
are indicated between BBR and control group (*).
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Figure 3.4 Regulation of Bsep/BSEP mRNA expression by BBR in cultured mouse
and human hepatoma cells.
Quantitative RT-PCR was conducted to determine mRNA levels of Bsep/BSEP in
cultured mouse Hepa1c1c7 (A) and human SNU449 (B) hepatoma cells following BBR
treatment (0, 5, 10 or 30 µM) for 24 hours. Data are expressed as mean ± S.E.,
(n=3/treatment). Statistical differences (p <0.05) are indicated between BBR and control
group (*).
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Figure 3.5 Regulation of Bsep/BSEP protein expression by BBR in cultured mouse
and human hepatoma cells.
Mouse Hepa1c1c7 and human SNU449 hepatoma cells, in triplicate, were treated with
BBR (0, 5, or 10 µM) for 48 hours. Cytosolic and membrane proteins, extracted from
mouse (A) and human (B) hepatoma cells were analyzed for Western blotting of
Bsep/BSEP protein expression. Data are expressed as mean ± S.E., (n=3/treatment).
Statistical differences (p <0.05) are indicated between BBR and control group (*).
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Figure 3.6 Immunocytochemistry staining of Bsep/BSEP protein in BBR-treated
mouse and human hepatoma cells.
Immunocytochemistry staining of Bsep/BSEP protein in BBR treated mouse Hepa1c1c7
(A, top panel) and human SNU449 (A, bottom panel) hepatoma cells. 200×
magnification, (Scale bar: 100 μm). Counting of Bsep/BSEP positive cells in a total of
1,000-1,500 cells (averaged on 20 random fields) per treatment in BBR-treated mouse (B,
top panel) and human (B, bottom panel) hepatoma cells. Statistical differences (p <0.05)
are indicated between BBR and control group (*).
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1.3. BBR Increased Cellular Efflux of Bsep Substrate in Hepatoma Cells
Bsep/BSEP efflux function was assessed by monitoring cellular efflux of
dichlorofluorescin diacetate, a selective Bsep substrate, into the culture medium. As
shown in Fig. 3.7, BBR treatment leads to an increase of dichlorofluorescin diacetate
concentrations in culture medium of both mouse Hepa1c1c7 and human SNU449
hepatoma cells. Accordingly, BBR treatment produces a decrease of dichlorofluorescin
diacetate concentrations in the cell lysates of both mouse and human hepatoma cells (Fig.
3.7A and B).
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Figure 3.7 BBR enhances Bsep/BSEP efflux function in cultured mouse and human
hepatoma cells.
Mouse Hepa1c1c7 and human SNU449 hepatoma cells, in triplicate, were treated with
BBR (10 µM) for 48 hours. Efflux of dichlorofluorescin diacetate, a selective Bsep
substrate was measured in mouse (A) and human (B) hepatoma cells. All data are
expressed as mean ± S.E., (n=3/treatment). Statistical differences (p <0.05) are indicated
between BBR and control group (*).
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1.4. BBR Activates Nrf2 Signaling in Hepatoma Cells but not in Mouse Livers
BBR dose-dependently induced mRNA expression of Ho-1 and Nqo-1, two known
Nrf2-target genes in wild-type (Fig. 3.8A) but not in Nrf2-null mouse livers (Fig. 3.8B).
However, in wild-type mouse livers, BBR did not significantly increase nuclear Nrf2
protein level (Fig. 3.9).
In addition, BBR induced mRNA expression of Ho-1/HO-1 and Nqo-1/NQO-1 in
both mouse Hepa1c1c7 (Fig. 3.10A) and human SNU449 (Fig. 3.10B) hepatoma cells.
BBR also increased nuclear levels of Nrf2/NRF2 proteins (Fig. 3.11A and B), as well as
the relative number of Nrf2/NRF2 protein-positive cells (Fig. 3.12A and B) in mouse and
human hepatoma cells.
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Figure 3.8 Regulation of mRNA expression of Ho-1 and Nqo-1 by BBR in wild-type
and Nrf2-null mouse livers.
Adult male C57BL/6 wild-type and age-matched male Nrf2-null mice were orally treated
with BBR (0, 30 or 100 mg/kg) once daily for 14 days (n=6/treatment). The mouse livers
were collected 14 days later and then processed for quantitative RT-PCR analysis of
mRNA expression of Ho-1 and Nqo-1 in wild-type (A) and Nrf2-null (B) mouse livers.
Statistical differences (p <0.05) are indicated between BBR and control group (*).
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Figure 3.9 Regulation of cytosolic and nuclear Nrf2 protein levels by BBR in mouse
livers.
Adult male C57BL/6 wild-type mice were orally treated with BBR (0, 30 or 100 mg/kg)
once daily for 14 days (n=6/treatment). Cytosolic and nuclear proteins, extracted from
wild-type mouse livers were processed for Western blotting of Nrf2 protein expression.
Statistical differences (p <0.05) are indicated between BBR and control group (*).
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Figure 3.10 Regulation of mRNA expression of Ho-1/HO-1 and Nqo-1/NQO-1 in
cultured mouse and human hepatoma cells.
Quantitative RT-PCR analysis of mRNA expression of Nrf2/NRF2-targte genes, Ho1/NO-1 and Nqo-1/NQO-1 in cultured mouse Hepa1c1c7 (A) and human SNU449 (B)
hepatoma cells following BBR treatment (0, 5, 10 or 30 µM). All data are expressed as
mean ± S.E., (n=3/treatment). Statistical differences (p <0.05) are indicated between BBR
and control group (*).
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Figure 3.11 Regulation of nuclear Nrf2/NRF2 protein level in cultured mouse and
human hepatoma cells.
Mouse Hepa1c1c7 and human SNU449 hepatoma cells were treated with BBR (0, 5, or
10 µM), in triplicate for 48 hours. Cytosolic and nuclear proteins, extracted from m ouse
(A) and human (B) hepatoma cells were analyzed for Western blotting of Nrf2/NRF2
protein expression. All data are expressed as mean ± S.E., (n=3/treatment). Statistical
differences (p <0.05) are indicated between BBR and control group (*).
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Figure 3.12 Immunocytochemistry staining of Nrf2/NRF2 protein in BBR-treated
mouse and human hepatoma cells.
Immunocytochemistry staining of Nrf2/NRF2 protein in BBR treated mouse Hepa1c1c7
(A, top panel) and human SNU449 (A, bottom panel) hepatoma cells. 200×
magnification, (Scale bar: 100 μm). Counting of Nrf2/NRF2 positive cells with a total of
1,000-1,500 cells (averaged on 20 random fields) in BBR or control treated mouse (B,
top panel) and human (B, bottom panel) hepatoma cells. Statistical differences (p <0.05)
are indicated between BBR and control group (*).
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1.5. The Impact of Nrf2/NRF2 mRNA Silencing on BBR-induced Mouse and
Human Bsep/BSEP Expression
In mouse hepatoma cells, Nrf2 siRNA treatment reduced Nrf2 mRNA levels about
75%, and largely repressed BBR-induced Bsep mRNA expression (Fig. 3.13). BBR still
slightly increased Bsep mRNA expression after Nrf2 silence.
In human hepatoma cells, NRF2 siRNA treatment knocked down NRF2 mRNA
levels more than 86%, and almost completely abolished BBR-induced BSEP mRNA
expression (Fig. 3.14).
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Figure 3.13 Nrf2 silence attenuated BBR-induced mouse Bsep expression.
Mouse Hepa1c1c7 hepatoma cells were treated with BBR (10 µM), in triplicate in the
presence or absence of Nrf2 siRNA for 24 hours. Quantitative RT-PCR analysis for
mRNA expression of Nrf2 (Left panel) and Bsep (Right panel) was determined in mouse
hepatoma cells. All data are expressed as mean ± S.E., (n=3/treatment). Statistical
differences (p <0.05) are indicated between BBR and control group (*), or between with
Nrf2 siRNA treatment and without Nrf2 siRNA treatment (#).
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Figure 3.14 NRF2 silence abolished BBR-induced human BSEP expression.
Human SNU449 hepatoma cells were treated with BBR (10 µM), in triplicated in the
presence or absence of NRF2 siRNA for 24 hours. Quantitative RT-PCR analysis for
mRNA expression of NRF2 (Left panel) and BSEP (Right panel) was next determined in
human hepatoma cells. All data are expressed as mean ± S.E., (n=3/treatment). Statistical
differences (p <0.05) are indicated between BBR and control group (*), or between with
NRF2 siRNA treatment and without NRF2 siRNA treatment (#).
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1.6. Removal of Putative NRF2 ARE from Bsep/BSEP Promoter Results in
Altered Promoter Activity
To determine the role of Nrf2 signaling in BBR-induced mouse and human
Bsep/BSEP expression, we engineered a series of recombinant pGL3 reporter constructs
containing different lengths of Bsep/BSEP promoters, as indicated in Figs. 3.15, 3.16 and
3.17. Luciferase activities that were driven by the 2.9-kb mouse and 3.7-kb human
Bsep/BSEP gene promoters, were both concentration-dependently induced by BBR (Fig.
3.15A and B).
In mouse hepatoma cells, luciferase reporter activity driven by 2.9 -kb mouse Bsep
promoter (ranged from -2,843 to +85bp) with a putative antioxidative response element
(ARE) located at -2,760 bp upstream of transcriptional start site (Fig. 3.16) is induced by
BBR treatment in a concentration-dependent manner. In addition, we also engineered a
truncated Bsep promoter that does not contain putative ARE (ranged from -2035 to
+85bp) into pGL3 basic vector (Fig. 3.16). To our surprise, the luciferase activity of the
truncated mouse Bsep promoter-driven pGL3 construct was even increased more by BBR
treatment as compared to 2.9-kb mouse Bsep promoter-driven pGL3 construct, indicating
that Nrf2 activation may suppress mouse Bsep expression.
In human hepatoma cells, the 3.7-kb human BSEP promoter (ranged from -3,602 to
+78bp), which contains one putative ARE located at -100 to +78bp relative to
transcriptional start site can be activated by BBR treatment (Fig. 3.17). We also
engineered a shorter fragment of BSEP promoter with one putative ARE, as depicted in
Fig. 2.16 to determine whether enhancer regulated human BSEP expression. The result
showed that BBR still increased luciferase activity in these constructs with one putative
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ARE. In contrast, the truncated human BSEP promoter that does not contain the putative
ARE, as depicted in Fig. 3.17, cannot be activated by BBR treatment. This indicates that
the putative ARE in human Bsep gene promoter is essential for BBR to induce human
BSEP expression.
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Figure 3.15 The impact of BBR on the activation of mouse and human Bsep/BSEP
promoter determined by dual luciferase reporter assays in cultured mouse and
human hepatoma cells.
Bsep/BSEP gene promoter-driven recombinant pGL3 reporter constructs were transfected
into hepatoma cells. The regulation of luciferase activity, which is driven mouse or
human Bsep/BSEP gene promoter was determined in mouse Hepa1c1c7 (A) and human
SNU449 (B) hepatoma cells following BBR treatment (0, 10, or 30µM) for 48 hours. All
data are expressed as mean ± S.E., (n=3/treatment). Statistical differences (p <0.05) are
indicated between BBR and control group (*).
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Figure 3.16 The impact of removal of putative ARE that is located in the Bsep gene
promoter on the BBR-activated mouse Bsep promoter.
After deletion of putative ARE (-2,770 to -2,760) in the mouse Bsep promoter, BBR
treatment (0, 5, or 10 µM) activated Bsep gene promoter even stronger in mouse
hepatoma cells. All data are expressed as mean ± S.E., (n=3/treatment). Statistical
differences (p <0.05) are indicated between BBR and control group (*), or between mBsep promoter groups (#).
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Fig. 3.17 The impact of removal of putative ARE that is located in human BSEP
gene promoter on the BBR-activated human BSEP promoter.
Compared to 3.7-kb human BSEP promoter (-3,602 to +78) and truncated 0.4-kb human
BSEP promoter (-299 to +78), deletion of putative ARE (-113 to -103) on human BSEP
promoter led to no more activation of human BSEP gene promoter by any concentration
of BBR treatment (0, 5, or 10 µM) in human hepatoma cells. All data are expressed as
mean ± S.E., (n=3/treatment). Statistical differences (p <0.05) are indicated between BBR
and control group (*), or between H-BSEP promoter groups (#).
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2. Regulation of Mouse Bsep by BBR via TLR4 Inactivation
2.1. LPS Did Not Increase Serum Levels of Liver Injury Biomarkers in Wildtype C3H/OuJ Mice
LPS at 2 mg/kg did not increase serum levels of ALT or AST in wild-type C3H/OuJ
mice (Fig. 3.18A and B). In addition, BBR or BBR pre-treatment did not alter serum
levels of ALT or AST.
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Figure 3.18 LPS did not increase serum levels of ALT or AST in wild-type mice
Wild-type C3H/OuJ mouse sera were collected after BBR treatment (100 mg/kg; p.o.)
once daily for 7 days and/or LPS treatment (2 mg/kg; i.p.) once on day 7 for 12 hours
(n=6/treatment). Serum levels of ALT (A) and AST (B) in mice were measured (n=
6/treatment). Statistical differences (p <0.05) are indicated between treatment and control
group (*).
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2.2. BBR Relieved LPS-Induced Liver Injury and Inflammation in Wild-type
C3H/OuJ but not in TLR4-mutated C3H/HeJ Mouse Livers
BBR did not induce liver injury in wild-type C3H/OuJ mouse livers (Figs. 3.19).
LPS induced apparent liver injury and inflammation, evidenced by cell swelling, diluted
and congested sinusoidal space, and increased number of infiltrated immune cells (Figs.
3.19). Pre-treatment of BBR attenuated LPS-induced liver injury and inflammation, as
indicated by recovered normal cell morphology and decreased number of infiltrated
immune cells (Fig. 3.19). In contrast, in TL4-mutated C3H/HeJ mouse livers, LPS did not
induce obvious liver injury and inflammation (Fig. 3.20).
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Figure 3.19 LPS-induced liver injury was attenuated by BBR in wild-type C3H/OuJ
mouse livers.
Wild-type C3H/OuJ mouse livers were collected after BBR treatment (100 mg/kg; p.o.)
once daily for 7 days and/or LPS treatment (2 mg/kg; i.p.) once on day 7 for 12 hours and
processed for histology analysis (n=6/treatment). H & E staining of mouse livers
following BBR and/or LPS treatment. 200× magnification, (Scale bar: 200 μm). Green
cycle: cell damage; Black arrowhead, diluted sinusoidal space; Yellow shorter arrow:
infiltrated immune cells.
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Figure 3.20 LPS did not induce liver injury in TLR4-mutated C3H/HeJ mouse
livers.
TLR4-mutated C3H/HeJ mouse livers were collected after BBR treatment (100 mg/kg;
p.o.) once daily for 7 days and/or LPS treatment (2 mg/kg; i.p.) once on day 7 for 12
hours and processed for histology analysis (n=6/treatment). H & E staining of mouse
livers following BBR and/or LPS treatment. 200× magnification, (Scale bar: 200 μm).
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2.3. BBR Reversed LPS-Inhibited Bsep Expression Through Suppressing
TLR4-NF-кB Signaling
In wild-type C3H/OuJ mouse livers, BBR induced Bsep mRNA expression but LPS
decreased Bsep mRNA expression (Fig. 3.21A). Pre-treatment of BBR reversed LPSinhibited Bsep expression. In contrast, in TLR4-mutated C3H/HeJ mouse livers, LPS did
not decrease Bsep mRNA expression (Fig. 3.21B). In addition, pre-treatment of BBR did
not alter Bsep expression as compared to LPS alone.
BBR also increased membrane Bsep protein expression but LPS decreased
membrane Bsep protein expression in wild-type C3H/OuJ mouse livers (Fig. 3.22A). Pretreatment of BBR reversed LPS-inhibited Bsep protein expression (Fig. 3.22A). In
contrast, in TLR4-mutated C3H/HeJ mouse livers, LPS did not reduce Bsep protein
expression (Fig. 3.22B). In addition, pre-treatment of BBR also tended to increase Bsep
protein level in TLR4-mutated C3H/HeJ mouse livers (Fig. 3.22B).
We next determined the impact of BBR on NF-кB, the downstream molecules of
TLR4 signaling. In wild-type C3H/OuJ mouse livers, LPS increased nuclear level of p65NF-кB protein (Fig. 3.23A). Pre-treatment of BBR inhibited the nuclear translocation of
p65-NF-кB protein. In contrast, in TLR4-mutated C3H/HeJ mouse livers, LPS did not
increase nuclear level of p65-NF-кB protein (Fig. 3.23B).
In addition, LPS induced NF-кB downstream cytokine genes, such as TNF-α, IL-1β
and IL-6 in wild-type C3H/OuJ mouse livers (Figs. 3.24A, B and C). Pre-treatment of
BBR reversed LPS-induced mRNA expression of cytokine genes. In contrast, LPS did
not induce mRNA expression of TNF-α in TLR4-mutated C3H/HeJ mouse livers (Fig.
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3.24A). Compared to wild-type mouse livers, TLR4-mutated C3H/HeJ mouse livers also
showed lower mRNA levels of IL-1β and IL-6 after LPS treatment (Figs. 3.24B and C).
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Figure 3.21 LPS-inhibited Bsep mRNA expression was reversed by BBR pretreatment in mouse livers.
Wild-type C3H/OuJ and TLR4-mutated C3H/HeJ mice were treated with BBR (100
mg/kg; p.o.) once daily for 7 days or/and a single dose of LPS (2 mg/kg; i.p.) on day 7 for
12 hours (n=6/treatment). Quantitative RT-PCR analysis of mRNA expression of Bsep in
wild-type (Fig. 3.21A) and TLR4-mutated (Fig. 3.21B) mouse livers. Statistical
differences (p <0.05) are indicated between BBR and control group (*).
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Figure 3.22 LPS-inhibited Bsep protein expression was reversed by BBR pretreatment in mouse livers.
Wild-type C3H/OuJ and TLR4-mutated C3H/HeJ mice were treated with BBR (100
mg/kg; p.o.) once daily for 7 days or/and a single dose of LPS (2 mg/kg; i.p.) on day 7 for
12 hours. Membrane proteins extracted from wile-type (A) and TLR4-mutated (B) mouse
livers were analyzed for Western blotting of Bsep protein expression. Statistical
differences (p <0.05) are indicated between BBR and control group (*).
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Figure 3.23 LPS-induced p65-NF-kB protein expression was attenuated by BBR
pre-treatment in mouse livers.
Wild-type C3H/OuJ and TLR4-mutated C3H/HeJ mice were treated with BBR (100
mg/kg; p.o.) once daily for 7 days or/and a single dose of LPS (2 mg/kg; i.p.) on day 7 for
12 hours (n=6/treatment). Nuclear proteins extracted from wile-type (A) and TLR4mutated (B) mouse livers were analyzed for Western blotting of p65-NF-kB protein
expression. Statistical differences (p <0.05) are indicated between BBR and control group
(*).
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Figure 3.24 LPS-induced cytokine mRNA expression was attenuated by BBR pretreatment in mouse livers.
Wild-type C3H/OuJ and TLR4-mutated C3H/HeJ mice were treated with BBR (100
mg/kg; p.o.) once daily for 7 days or/and a single dose of LPS (2 mg/kg; i.p.) on day 7 for
12 hours (n=6/treatment). Quantitative RT-PCR analysis of mRNA expression of TNF-α,
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IL-1β and IL-6 in wild-type and TLR4-mutated mouse livers (Figs. 3.24A, B and C).
Statistical differences (p <0.05) are indicated between BBR and control group (*).
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2.4. BBR Reversed TLR4-Inhibited Bsep mRNA Expression in Mouse
Hepatoma Cells
As shown in Fig. 3.25A, LPS reduced Bsep mRNA expression in mouse hepatoma
cells. Pre-treatment of BBR reversed LPS-decreased Bsep mRNA expression (Fig.
3.25A). In addition, Tak242, the TLR4 inhibitor, also reversed LPS-suppressed Bsep
mRNA expression (Fig. 3.25B).
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Figure 3.25 LPS-repressed Bsep mRNA expression was reversed by pre-treated with
BBR in cultured mouse hepatoma cells.
Mouse Hepa1c1c7 hepatoma cells, in triplicate, were treated with LPS (10 ng/mL) in the
presence or absence of BBR treatment (10 µM) or TLR4 inhibitor, TAK242 treatment
(0.3mM) for 24 hours. Quantitative RT-PCR analysis of mRNA expression of Bsep in
BBR (A) and TAK242 (B) treated mouse hepatoma cells. Data are expressed as
mean ± S.E (n=3/treatment). Statistical differences (p <0.05) are indicated between
treatment and control group (*).
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CHAPTER 4 DISCUSSION
It has been previously reported that goldenseal, in which BBR is the major active
component, promotes bile flow (Newall, et al., 1996). We recently also reported that
BBR promotes bile flow maybe via induction of cytochrome p450 (Cyp) 7a1, Ntcp and
Bsep, several bile acid-related genes in the liver, and that BBR induces Ntcp expression
via inhibiting Jak2-Stat5 signaling (Bu et al., 2017). The studies proposed in my
dissertation project characterized the underlying mechanisms by which BBR induces
mouse and human Bsep/BSEP expression. Bsep expression is primarily induced by FXR
signaling. However, the mechanisms other than FXR activation is responsible for BBRinduced Bsep expression because BBR below 300 mg/kg did not activate FXR signaling
(Guo et al., 2016). In addition, it is well-known that activation of FXR will downregulate Ntcp and Cyp7a1 expression. However, as mentioned above, BBR actually
induced the expression of Ntcp and Cyp7a1. In my dissertation, I reported that BBR
induced Bsep/BSEP expression and transport function in mouse liver, as well as in mouse
and human hepatoma cells. In addition, BBR induced human BSEP expression through
NRF2 activation and induced mouse Bsep expression most likely through TLR4
inhibition.
First, similar as previously reported, BBR did not induce apparent liver injury,
evidenced by no change in mouse behavior and body weight, as well as serum levels of
ALT, a biomarker of liver injury (Fig. 3.1A). BBR also reduced serum levels of glucose
and lipids in mice, indicating potential hepatoprotective roles (Yin et al., 2008; Zhao et
al., 2019). It has been reported that BBR alone did not induce oxidative stress in both
mouse liver and cultured hepatocytes (Dkhil et al., 2014; Liu et al., 2012). Pre-treatment
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of BBR even inhibited tert-butyl hydroperoxide-induced ROS and lipid peroxidation in
rat liver (Hwang et al., 2002). Thus, BBR is a potential Nrf2 activator but not a prooxide.
In addition, BBR increased Bsep/BSEP mRNA and protein expression in mouse
liver (Figs. 3.2 and 3.3), as well as in mouse and human hepatoma cells (Figs. 3.4, 3.5
and 3.6). Consistent to Bsep/BSEP gene regulation, BBR also enhanced Bsep/BSEP
efflux transport function, evidenced by increased cellular efflux of dihydrofluorescein
diacetate, a selective Bsep substrate in both mouse and human hepatoma cells (Wang et
al., 2003) (Fig. 3.7).
I next determined the impact of Nrf2 activation on Bsep/BSEP expression by BBR.
Similar to previous reports, BBR activated Nrf2 signaling, evidenced by increased
mRNA expression of Nrf2-target genes, including Ho-1/HO-1 and Nqo-1/NQO-1, in
wild-type mouse livers (Fig. 3.8A) and mouse and human hepatoma cells (Fig. 3.10), but
not in Nrf2-null mouse livers (Fig. 3.8B). To our surprise, BBR did not induce nuclear
translocation of Nrf2 protein in mouse livers (Fig. 3.9), which was contradictory to
previous reports (Deng et al., 2019; Mo et al., 2012; Hsu et al., 2012). This discrepancy
between our and other results could be interpreted by species and model difference, as
well as different time period of BRR treatment. In contrast, as shown in Fig. 3.11 and
3.12, BBR induced nuclear translocation of Nrf2/NRF2 protein in both mouse and human
hepatoma cells. This result was consistent to previous studies, BBR activated Nrf2
signaling in cultured neuron and human hepatoma cells (Hsu et al., 2012 and 2013; Sun
et al., 2017). The differences regarding Nrf2 activation by BBR between mouse liver and
mouse hepatoma cells is most likely due to loss of hepatocyte morphology and polarity in
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cultured hepatoma cells, which leads to reduced expression or even complete loss of drug
metabolized enzymes and transporters (Bachmann et al., 2015). Consequently, without
normal metabolism and efflux function, BBR can stay inside the hepatoma cells for
longer time as compared in the liver.
Nrf2-null mouse model and siRNA knockdown were also applied to investigate the
role of Nrf2/NRF2 activation in BBR-induced Bsep/BSEP expression. As shown in Fig.
3.3B, BBR increased Bsep protein expression in the membrane of both wild -type and
Nrf2-null mouse livers, indicating that BBR-induced Bsep expression is independent of
Nrf2 activation in mouse liver. This was consistent to several reports, which documented
that mouse Bsep was not a downstream target of Nrf2 signaling (Klaassen and Reisman,
2010; Reisman et al.,2009; Cheng et al., 2007). In addition, a potential Nrf2 activator,
ursodeoxycholic acid did not increase Bsep expression in mouse liver (Okada et al.,
2008). Next, we used Nrf2/NRF2 siRNA to knockdown mRNA expression of Nrf2/NRF2
in hepatoma cells. In Nrf2-silenced mouse hepatoma cells, BBR still slightly increased
Bsep mRNA expression (Fig. 3.13). This indicated that Nrf2 may be not sole ly
responsible for BBR to induce mouse Bsep expression. In contrast, in NRF2 -silenced
human hepatoma cells, BBR-induced BSEP induction was blocked completely,
indicating the necessity of NRF2 activation for BBR-induced human BSEP expression
(Fig. 3.14).
To further determine the role of putative Nrf2 response element(s) in the BBRinduced Bsep/BSEP gene expression, luciferase reported assays were processed.
Luciferase reported assays first showed that BBR activated mouse and human
Bsep/BSEP promoter activity (Fig. 3.15). Then, a series of Bsep/BSEP gene promoters
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with different lengths were cloned and then engineered cloned Bsep/BSEP gene
promoters into pGL3-basic reporter construct as depicted in Figs. 3.16 and 3.17. In
mouse hepatoma cells, BBR continued to increase the luciferase activity driven by mouse
Bsep gene promoters in which putative Nrf2 binding site does not exist, indicating that
Nrf2 activation was not required for BBR-induced mouse Bsep expression (Fig. 3.16). In
contrast, in human hepatoma cells, BBR can no longer increase the luciferase activities
that are driven by human BSEP gene promoters in which putative NRF2 binding site does
not exist (Fig. 3.17). The difference between mouse and human hepatoma cells is due to
species differences in the sequence of Bsep/BSEP gene promoter (Klaassen and Reisman,
2010).
Because BBR-induced mouse Bsep expression appeared not to be due to Nrf2
activation, we next determined whether other mechanisms are responsible for mouse
Bsep induction by BBR. Several reports showed that BBR inhibited TLR4 activity and
that TLR4-NF-kB inflammatory signaling repressed Bsep expression (Hsiang et al.,
2005; Enk et al., 2007; Chu et al., 2014). Therefore, we determined the impact of BBRrepressed TLR4 signaling on mouse Bsep expression.
Consistent to previous reports, pre-treatment of BBR inhibited LPS-induce liver
injury and inflammation in mouse liver (Chu et al., 2014; Lou et al., 2010). In wild-type
mice, LPS did not increase serum levels of ALT and AST (Fig. 3.18) but induced
apparent liver injury and inflammation in mouse liver (Fig. 3.19). LPS-induced liver
damage can be characterized by megatocytosis and dilated sinusoidal space (Liu et al.,
2018; Fang et al., 2013; Greuter and Shah, 2016). LPS also stimulated acute
inflammatory through activation of immune cells, such as macrophages/Kupffer cells and
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neutrophils in mouse liver, which was evidenced by increased number of cell infiltration
(Fig. 3.19) (Karlmark et al., 2008). In addition, LPS induced TLR4 downstream
molecules, NF-кB protein and its target cytokine expression (Figs. 3.23A and 3.24) (Chu
et al., 1999; Jiang et al., 2000). In contrast, pre-treatment of BBR attenuated LPSinduced liver injury and inflammation in histology study (Fig. 3.19), and also modulated
NF-кB signaling and its downstream gene expression (Figs. 3.23A and 3.24). The results
were similar to previous reports, showing that BBR inhibited TLR4-mediated
inflammation through inhibiting nuclear translocation of NF-кB protein and/or
production of cytokines (Enk et al., 2007; Chu et al., 2014; Lou et al., 2010).
Next, we determined the role of TLR4 signaling in BBR-induced mouse Bsep
expression. In mouse livers, LPS inhibited Bsep mRNA and protein expression (Figs.
3.21 and 3.22A) (Hsiang et al., 2005; Enk et al., 2007). However, pre-treatment of BBR
reversed LPS-decreased Bsep mRNA and protein expression (Figs. 3.21 and 3.22A). This
indicated that the suppression of TLR4 by BBR can up-regulate mouse Bsep expression.
To further investigate the role of TLR4 inhibition in mouse Bsep expression, we used
TLR4-mutated C3H/HeJ mouse model. Since TLR4 is dysfunctional in C3H/HeJ mouse
livers, LPS, as expected, did not induce liver injury and inflammation, and also did not
inhibit Bsep expression (Figs. 3.20 and 3.23B and 3.24) (Paik et al., 2003). This indicated
that TLR4 inactivation is a putative strategy to reverse inflammation mediated Bsep
inhibition. Furthermore, BBR and TAK242, a known TLR4 inhibitor, both reversed LPSrepressed Bsep expression in cultured mouse hepatoma cells (Fig. 3.25). Therefore, it is
most likely that BBR inhibits TLR4 signaling and consequently induces mouse Bsep
expression.
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Taken together, our results demonstrated that BBR increased mouse and human
Bsep/BSEP expression. In addition, NRF2 activation contributes to BBR-induced human
BSEP expression. TLR4 inhibition most likely contributes to BBR-induced mouse Bsep
expression.
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CHAPTER 5 SUMMARY AND CONCLUSIONS
With extensive investigation, more and more therapeutic effects of BBR have been
revealed, including anti-inflammatory, anti-diabetic, and anti-cancer effects (Puthdee et
al., 2017; Lee et al., 2006; Diaz et al., 2015; Doggrell, 2005). In addition, BBR has been
recognized as a promising candidate to treat liver diseases, which is most likely due to its
anti-oxidative and anti-inflammatory properties (Vuddanda et al., 2010). We and others
also demonstrated that BBR can promote bile flow (Newall, et al., 1996; Bu et al., 2017).
As an essential approach for absorption of lipid-soluble vitamins and elimination of
xenobiotic, bile acid homeostasis is tightly regulated by multiple nuclear receptors and
transporters (Anwer, 2004). For example, we previously reported that BBR induced
mouse and human Ntcp/NTCP expression through down-regulation of Jak2-Stat5
signaling (Bu et al., 2017). In this study, I also showed that BBR induced mouse and
human Bsep/BSEP expression. However, the underlying mechanism is not known. The
overall goal of my dissertation is to determine the underlying mechanisms by which BBR
induces mouse and human Bsep/BSEP expression, especially the roles of Nrf2 activation
and TLR4 inhibition.
In my dissertation, I first determined whether BBR-induced Bsep/BSEP expression
can lead to enhanced transport function. As expected, BBR enhanced Bsep/BSEP efflux
function, evidenced by increased efflux of dichlorofluorescin diacetate, the selective Bsep
substrate, out of mouse and human hepatoma cells. Therefore, BBR-induced Bsep/BSEP
expression consequently leads to increased cellular efflux activity of Bsep/BSEP.
Next, I determined the involvement of Nrf2 activation in BBR-induced Bsep/BSEP
expression. The results first showed that BBR activated Nrf2 signaling, evidenced by
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increased nuclear translocation of Nrf2 protein and increased expression of Nqo -1/NQO1 and Ho-1/HO-1, two known Nrf2 target genes in mouse and human hepatoma cells.
However, BBR apparently did not activate Nrf2 signaling in mouse liver. In addition,
BBR increased mouse Bsep expression in both wild-type and Nrf2-null mouse livers, and
even can activate mouse Bsep gene promoter in both presence and absence of putative
ARE. These results indicated that Nrf2 is not essential for BBR to induce mouse Bsep
expression. In contrast, after removal of putative ARE in human BSEP gene promoter, or
in NRF2-silenced human hepatoma cells, BBR no longer induced human BSEP
expression. Therefore, NRF2 activation is essential for BBR to induce human BSEP
expression. Taken together, Nrf2/NRF2 plays important role in up-regulation of human
BSEP, but not mouse Bsep by BBR.
I also investigated the impact of TLR4 inhibition on BBR-induced mouse Bsep
expression by using TLR4-mutated C3H/HeJ mouse model. My findings demonstrated
that pre-treatment of BBR suppressed TLR4-induced inflammation and then recovered
Bsep expression in wild-type but not in TLR4-mutated mouse livers. In mouse hepatoma
cells, BBR also reversed LPS-decreased Bsep expression. Because TLR4-NF-кB has
been previously reported to suppress Bsep expression (Elferink et al., 2004; Trauner et
al., 1998; Hartmann et al., 2002), BBR-induced mouse Bsep expression maybe via TLR4
suppression.
My results further suggest that BBR is a promising therapeutic drug to manage
cholestatic liver disease. However, to apply BBR for cholestasis therapy in patients,
several limitations need to be taken into consideration. First, poor bioavailability of BBR
is a big challenge. To solve this issue, silver nanoparticles containing BBR have been
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designed to improve its bioavailability (Ling et al., 2008). Second, it has been reported
that BBR metabolites may have similar effects as BBR does. Therefore, it merits further
investigation of Bsep regulation by BBR metabolites on. Third, due to the differences
between in vivo and in vitro conditions, it is necessary to determine whether BBR
similarly enhances Bsep efflux function in the whole animal. To perform this study,
radiolabeled [18F] LCATD (LithoCholic Acid Triazole Derivative), which is a Bsep
substrate with radioactivity, may be used to evaluate the in vivo Bsep efflux function after
BBR treatment (Testa et al., 2018). Fourth, we may also consider using primary human
hepatocytes and HepaRG cells. These cells have normal enzyme activity and transporter
function, which are good models to investigate the effects of BBR in human livers.
In addition, my dissertation research also paves a way for future direction. In the
studies proposed in Hypothesis I, the underlying mechanisms of how BBR activates
human NRF2 signaling is not investigated. It has been suggested that PI3K/Akt signaling
and epigenetic gene regulation can lead to human NRF2 activation (Ref). Therefore,
these two signaling mechanisms can be further evaluated to determine whether they
contribute to human NRF2 activation by BBR. In the studies proposed in Hypothesis II, I
only reported that TLR4 repression may contribute to BBR-induced mouse Bsep
expression. It merits further investigation, such as how TLR4 downstream signaling
molecules, such as NF-кB or AP-1, contribute to BBR-induced mouse Bsep expression.
Last, regulation of other bile flow-related transporters by BBR can also be investigated.
For example, it has already been reported that Mdr2 can be induced by BBR and could be
another potential target for cholestasis management (Guo et al., 2016).
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In conclusion, my dissertation demonstrates that BBR induced mouse and human
Bsep/BSEP expression. In addition, BBR induced human BSEP expression via NRF2
activation, and induces mouse Bsep expression most likely via TLR4 suppression.
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